Healthcare company Boston Scientific purchased its peer, Guidant, in 2006 for the princely sum of $27 billion. At the time Guidant was viewed as a high return, high growth company. Boston made two major errors. The deal price assumed a continuation of Guidance’s growth and returns. Boston’s share price – and the debt pile used to fund the deal – required it. It’s a salutary tale.....
